Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galena, ImmunoCellular Caught Up In US SEC Clampdown On Fraudulent Stock Promotions

Executive Summary

Four biopharma firms allegedly paid writers to post positive articles about their stocks that were merely "paid advertisements"; in settlement, former CEOs of Galena and ImmunoCellular barred from being officer or director for five years and ordered to pay $1.3m and $2.9m, respectively.

You may also be interested in...



Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace

Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."

Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'

Pivotal and Biomatics launch new VC funds totaling $300m and $200m, respectively; Spero raises a $51.7m Series C round; BeyondSpring is March's only US IPO, so far; Aurinia and TG Therapeutics capitalize on positive data with secondary offerings; and Galena hires a "strategic review" advisor.

SEC probe hits Galena hard

Shares of Galena Biopharma went into a tailspin on 18 March, plunging 21% after the company revealed the Securities and Exchange Commission (SEC) had opened an investigation into the firm and an outside investor relations company the biotech retained last year.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel